

1 ***Borrelia burgdorferi* BB0346 is an Essential, Structurally Variant LoIA**
2 **Homolog that is Primarily Required for Homeostatic Localization of**
3 **Periplasmic Lipoproteins**

4

5 Bryan T. Murphy^a, Jacob J. Wiepen^{a*}, Danielle E. Graham^{b†}, Selene K. Swanson^c, Maithri M. Kashipathy^d,
6 Anne Cooper^{d,e}, Kevin P. Battaile^f, David K. Johnson^e, Laurence Florens^c, Jon S. Blevins^b, Scott Lovell^{d,e},
7 and Wolfram R. Zückert^a

8

9 ^a*University of Kansas School of Medicine, Department of Microbiology, Molecular Genetics &*
10 *Immunology, Kansas City, Kansas*

11 ^b*University of Arkansas for Medical Sciences, Department of Microbiology & Immunology, Little Rock,*
12 *Arkansas*

13 ^c*Stowers Institute, Kansas City, Missouri*

14 ^d*Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington, 98109, USA*

15 ^e*University of Kansas, Protein Structure and X-ray Crystallography Laboratory, Lawrence, Kansas*

16 ^f*New York Structural Biology Center, Upton, New York*

17

18 **Present addresses:** *Advanced Surgical Associates, Lee's Summit, Missouri; †Department of Biological
19 and Forensic Sciences, Fayetteville State University, Fayetteville, North Carolina

20

21 **Corresponding author:** Wolfram R. Zückert, Ph.D., University of Kansas School of Medicine,
22 Department of Microbiology, Molecular Genetics & Immunology, MS 3029, 3025 Wahl Hall West, 3901
23 Rainbow Boulevard, Kansas City, KS 66160, U.S.A. Tel. (913) 588-7061, Email: wzueckert@kumc.edu

24

25 **ABSTRACT**

26 In diderm bacteria, the Lol pathway canonically mediates the periplasmic transport of lipoproteins from
27 the inner membrane (IM) to the outer membrane (OM) and therefore plays an essential role in bacterial
28 envelope homeostasis. After extrusion of modified lipoproteins from the IM via the LolCDE complex, the
29 periplasmic chaperone LolA carries lipoproteins through the periplasm and transfers them to the OM
30 lipoprotein insertase LolB, itself a lipoprotein with a LolA-like fold. Yet, LolB homologs appear restricted
31 to γ -proteobacteria and are missing from spirochetes like the tick-borne Lyme disease pathogen *Borrelia*
32 *burgdorferi*, suggesting a different hand-off mechanism at the OM. Here, we solved the crystal structure
33 of the *B. burgdorferi* LolA homolog BB0346 (LolA_{Bb}) at 1.9 Å resolution. We identified multiple structural
34 deviations in comparative analyses to other solved LolA structures, particularly a unique LolB-like
35 protruding loop domain. LolA_{Bb} failed to complement an *Escherichia coli* lolA knockout, even after codon
36 optimization, signal I peptide adaptation, and a C-terminal chimerization which had allowed for
37 complementation with an α -proteobacterial LolA. Analysis of a conditional *B. burgdorferi* lolA knockout
38 strain indicated that LolA_{Bb} was essential for growth. Intriguingly, protein localization assays indicated
39 that initial depletion of LolA_{Bb} led to an emerging mislocalization of both IM and periplasmic OM
40 lipoproteins, but not surface lipoproteins. Together, these findings further support the presence of two
41 separate primary secretion pathways for periplasmic and surface OM lipoproteins in *B. burgdorferi* and
42 suggest that the distinct structural features of LolA_{Bb} allow it to function in a unique LolB-deficient
43 lipoprotein sorting system. (250 words)

44

45 **SIGNIFICANCE**

46 *Borrelia* spirochetes causing Lyme disease and relapsing fever have unusual double-membrane
47 envelopes that instead of lipopolysaccharide (LPS) display abundant surface lipoproteins. We recently
48 showed that secretion of these surface lipoproteins in *Borrelia burgdorferi* depends on a distant homolog
49 of the canonical LPS outer membrane translocase LptD. Here, we probed the role of the *B. burgdorferi*

50 Lol pathway in lipoprotein sorting and secretion. We show that the periplasmic chaperone LolA is
51 essential, functionally different from *E. coli* LolA, with structural features of a bifunctional lipoprotein
52 carrier protein operating without a downstream LolB outer membrane lipoprotein insertase. Depletion of
53 LolA did not impact surface lipoprotein localization but led to a marked mislocalization of inner membrane
54 lipoproteins to the outer membrane. This further supports two parallel, yet potentially interacting *Borrelia*
55 lipoprotein transport pathways that are responsible for either secreting surface lipoprotein virulence
56 factors or maintaining proper distribution of lipoproteins within the periplasmic space. (150 words)

57

58 INTRODUCTION

59 The Lyme disease spirochete *Borrelia burgdorferi* is a diderm bacterium with several envelope features
60 that distinguishes it from other evolutionarily distant gram-negative model organisms, such as lacking
61 lipopolysaccharide (LPS) on its outer surface, sequestering its flagella within the periplasm, or exhibiting
62 only a relatively thin layer of peptidoglycan that is more closely associated with the inner membrane (IM)
63 than the outer membrane (OM) of the cell (reviewed in ref. (1)). In lieu of LPS, *B. burgdorferi* expresses
64 an arsenal of more than 90 surface lipoproteins, which are known to mediate the majority of identified
65 interactions with tick vectors and mammalian hosts (reviewed in refs. (2, 3)) and appear to be secreted
66 by a distantly related version of the Lpt LPS transport system (4). Eight subsurface lipoproteins have
67 been identified at the inner leaflet of the OM (5). Currently, four of these subsurface lipoproteins have
68 known functional roles in envelope biogenesis or pathogenesis: Lp6.6 (BBA62) is abundant in OM protein
69 complexes, non-essential for in vitro growth but associated with the ability of the spirochetes to colonize
70 ticks (6-9), BB0323 is involved in maintaining OM integrity that also affects transmission and
71 pathogenicity (10-12), and BamD (BB0324) and BamB (BB0028) are the only two identified β -barrel
72 assembly machinery (BAM) complex lipoproteins with discrete functions (13).

73 Proper localization of OM lipoproteins is critical to their function and first requires the export of
74 pre-pro-lipoproteins with an N-terminal signal II sequence and lipobox motif through the cytoplasmic
75 membrane via the general secretory (Sec) pathway. Following translocation, a conserved cysteine

76 residue at the lipobox motif +1 site is modified by a series of three enzymes (Lgt, Lsp, and Lnt) to remove
77 the signal sequence and generate mature tri-acylated lipoproteins at the periplasmic leaflet of the IM
78 (reviewed in (14)). Extrusion of mature lipoproteins from the IM by the type VII ABC-transporter LolCDE
79 ultimately determines which lipoproteins will finally be transported to the inner leaflet of the OM by the
80 LolA periplasmic chaperone (15). In *E. coli* and other well studied γ -proteobacteria, intrinsic +2/+3/+4 “Lol
81 sorting signal” residues immediately following the lipidated cysteine putatively interact with the primary
82 membrane phospholipid phosphatidylethanolamine (PE) to retain IM lipoproteins. More specifically,
83 anionic amino acids at these positions are thought to act as a Lol avoidance signal by interacting with
84 cationic PE head amine groups (16). The additional clustered phospholipid chains from this interaction
85 then prevent LolE from acquiring the lipoprotein and starting the extrusion process. While *Borrelia* has
86 similarly charged phosphatidylcholine (PC) in place of PE, PC’s head amine group is sterically hindered
87 by trimethylation (17). This may explain why no “+2/3/4” Lol sorting signals have been identified (5, 18,
88 19). Spirochetes, like α -, δ - and ϵ -proteobacteria, also lack a detectable homolog for the OM lipoprotein
89 acceptor and insertase LolB, which acquires lipoproteins from LolA and inserts them into the periplasmic
90 leaflet of the OM via a small protruding loop domain containing a functionally relevant leucine residue
91 (20). Therefore, *Borrelia* likely uses different mechanisms for localizing periplasmic lipoproteins to the IM
92 or the periplasmic leaflet of the OM.

93 Here, we began studying the putative LolB-deficient lipoprotein sorting system of *Borrelia*
94 *burgdorferi* by solving the crystal structure of its LolA homolog BB0346 (*i.e.* LolA_{Bb}), the furthest
95 identifiable downstream component of the Lol pathway. We also tested for heterologous
96 complementation of a conditional *E. coli* *lolA* knockout and used a conditional *B. burgdorferi* *lolA* knockout
97 to assess the effects of LolA depletion on lipoprotein sorting and secretion. Our results provide first
98 insights into the role of a structurally variant spirochetal LolA lipoprotein carrier protein homolog in
99 maintaining a diderm envelope that is dominated by surface-localized lipoproteins.

101 **RESULTS**

102 ***B. burgdorferi* BB0346 is a LolA homolog that fails to complement *E. coli* LolA.** The NCBI
103 Conserved Domain Database annotates the product of open reading frame (ORF) BB_0346, located on
104 the linear chromosome of *B. burgdorferi*, as a LolA domain-containing protein (cd16325), which should
105 function in the periplasmic space after transport across the inner membrane by SecYEG and subsequent
106 cleavage by signal peptidase I (SPase I). Indeed, BB_0346 encodes for a 216-amino acid protein with a
107 predicted 17 amino acid-long signal I peptide (SSI; SignalP 6.0 SSI probability = 0.97 (21)).

108
109 Initial heterologous expression of the full-length BB_0346 ORF, but not BB_0346 missing the SSI peptide,
110 proved toxic to *E. coli*, inhibiting growth even from leaky expression under an uninduced *lac* promoter
111 (data not shown). We hypothesized that full-length BB_0346 was toxic to *E. coli* because it either (i) was
112 not properly recognized, processed, and secreted by the *E. coli* general secretion machinery, or (ii) was
113 able to partially interfere with the periplasmic Lol system machinery in *E. coli*, leading to aberrant OM
114 lipoprotein sorting. A comparison of the two signal I peptides showed that the *B. burgdorferi* SSI peptide
115 was shorter and had a more degenerate signal I peptidase recognition sequence than that of *E. coli* (**Fig.**
116 **1A**). In a series of experiments, we generated various chimeric *E. coli/B. burgdorferi* LolA fusion proteins
117 and tested them for toxicity and proper processing. Only the generation of a chimeric LolA construct
118 fusing the *E. coli* LolA SSI peptide to the mature *B. burgdorferi* LolA (mLolA_{Bb}) peptide eliminated toxicity
119 and produced a major protein band that was equal in size to the native LolA_{Bb} produced in *B. burgdorferi*
120 (**Fig. 1B**). This indicated that the *E. coli* SPase I (LepB) does not efficiently process the w.t. *B. burgdorferi*
121 protein, but that processing efficiency is increased for an N-terminal chimera with the *E. coli* LolA signal
122 peptide. Note that proper processing in *B. burgdorferi* appears independent of which SSI was used,
123 suggesting that processing of secreted non-lipidated proteins is more promiscuous in that system.
124 Fusions of either SSI to a superfolder GFP (sfGFP) reporter further demonstrated that the *B. burgdorferi*
125 SSI interferes with processing and secretion of proteins into the *E. coli* periplasmic space, producing

126 aggregates primarily located at the cell poles. In contrast, *E. coli* SSI-sfGFP fusions appeared more
127 soluble and evenly distributed (**Supplemental Fig. S1**).

128 Building on these data, we next tested whether *B. burgdorferi* LolA was able to complement *E.*
129 *coli* LolA using a conditional *E. coli* LolA knockout strain TT011 (22) (supplied by H. Tokuda). To reduce
130 other potential issues for proper expression in *E. coli*, we further modified the apparently processable
131 SSI_{Ec}-mLolA_{Bb} fusion by codon optimization. We also generated an additional chimera that included a C-
132 terminal adaptation which allowed a LolA homolog from the α -proteobacterium *Caulobacter vibrioides* to
133 be compatible with the LolCDE complex in *E. coli* (23) (**Supplemental Data Fig. S2**). None of the
134 chimeras were able to complement *E. coli* LolA and support growth (**Fig. 1C**), suggesting that *B.*
135 *burgdorferi* LolA had functionally unique properties. It should be noted that *E. coli* TT011 still expresses
136 OM lipoprotein Lpp, which is known to be toxic when mislocalized due to its linkage with peptidoglycan
137 (24). As previously described, the *lpp*-minus TT011 derivative, TT015, showed no basic growth defect
138 when LolA was depleted by removal of IPTG (22), so we were unable to test for complementation in that
139 background.

140

141 **BB0346 (LolA_{Bb}) is a structural LolA homolog with unique structural features.** Based on the
142 observed incompatibility with the *E. coli* Lol system, we wondered if the LolA_{Bb} structure might deviate
143 from canonical LolA homologs. We therefore solved its structure by X-ray crystallography. A signal
144 peptide-less BB_0346 sequence corresponding to the fully processed mature mLolA_{Bb} peptide was
145 amplified by PCR from *B. burgdorferi* type strain B31 genomic DNA and ligated into pET29b(+), which
146 provided a C-terminal hexa-histidine tag (**Supplemental Data Fig. S3A**). Note that the peptide
147 sequences of BB0346/LolA_{Bb} from strains 297 and B31 are identical. The resulting plasmid was used to
148 transform *E. coli* BL21(DE3) pLysS (Novagen). Soluble mLolA_{Bb} was purified from the bacterial cytoplasm
149 via two rounds of cobalt affinity chromatography separated by a single round of ion-exchange
150 chromatography (**Supplemental Data Fig. S3B**). Crystallization screening on the purified LolA_{Bb} is

151 described in the Materials & Methods section, and representative crystals are shown in **Supplemental**
152 **Data Fig. S3C**.

153 The final LolA_{Bb} model resolved to 1.9 Å and included residues spanning Q2 to Y195 (**Fig. 2**). The
154 residues that could not be modeled due to disorder are noted in **Supplemental Data Fig. S3A**. The
155 overall structure of LolA_{Bb} contains 12 β-strands and two α-helices. These secondary structure elements
156 adopt a partial β-barrel fold composed of 11 antiparallel β-strands (β1-11) and a single short strand (β12)
157 which are capped on one end by the two α-helices (**Figs. 2A-C**). Prominent positive electron density was
158 observed within the interior of the β-barrel that was ultimately modeled as a PEG molecule fragment
159 obtained from PEG 5000 MME in the crystallization solution (**Fig. 2D**). Therefore, this structure is referred
160 to as LolA_{Bb}-PEG (PDB accession number 7TPM) from this point forward. Data sets that were obtained
161 with crystals obtained in the absence of PEG also showed electron density in the LolA_{Bb} core, albeit to a
162 lesser extent. For example, refinement of LolA_{Bb} models against X-ray diffraction data collected on
163 crystals obtained from Proplex HT G2 (2 M ammonium sulfate, 100 mM sodium acetate pH 5.0) and H1
164 (2 M NaCl, 100 mM sodium citrate pH 6.0) produced weaker electron density in the core of LolA_{Bb}
165 (**Supplemental Data Fig. S4**). As such, it is conceivable that a polar lipid-like molecule was acquired
166 from the *E. coli* expression host and bound to LolA_{Bb} at low occupancy. Additionally, we observed more
167 prominent electron density in this region from crystals that were cryoprotected with PEG 200 instead of
168 glycerol, suggesting that the PEG molecule may displace any molecules that are acquired from the
169 expression host under these conditions (data not shown).

170 Within LolA_{Bb}-PEG, the PEG molecule is mainly surrounded by hydrophobic residues, but it forms
171 a direct hydrogen bond to Y41 (OH) and water mediated contact with S60 (OH) as shown in **Fig. 2E**. It
172 has a total accessible surface area of 574.4 Å², of which 567.1 Å² (98.7%) is buried in the core, forming
173 an interface with LolA_{Bb}-PEG that covers 461.9 Å² as determined by PISA (25). As such, the PEG
174 molecule is positioned within a hydrophobic pocket (**Fig. 2E**). In addition, a sodium ion was modeled
175 based on coordination geometry and bond distances (**Supplemental Data Fig. S5**). Interestingly,
176 subsequent LolA_{Bb} preparations also yielded crystals from 1.5 M ammonium sulfate, 0.1 M HEPES, pH

177 7.5 which were cryoprotected with 2.5M lithium sulfate (see Materials & Methods). In these crystals, a
178 large mass of positive electron density within the PEG binding site was ultimately modeled as steric acid
179 (LolA_{Bb}-SA). The steric acid molecule adopted a binding mode similar to the PEG molecule, as shown in
180 **Supplemental Data Fig. S6A.**

181 Superimposition of various solved LolA structures onto LolA_{Bb}-PEG using secondary structure
182 matching (SSM) (26) yielded the following RMSD deviations between C α atoms: *Pseudomonas*
183 *aeruginosa* (2W7Q, 2.86 Å, 146 residues), *E. coli* (1IWL, 2.95 Å, 131 residues), *Neisseria europaea*
184 (3BUU, 2.50 Å, 137 residues), *Yersinia pestis* (4KI3, 2.50 Å, 130 residues). As shown in **Fig. 3**, there is
185 displacement of both β -sheets and α -helices between these similar structures, and this accounts for the
186 somewhat large RMSD deviations. One major difference is observed in the loop between β 6 and α 2 in
187 LolA_{Bb}-PEG (α 3 in other LolA structures) which is moved out of the core to accommodate binding of the
188 PEG molecule. In the γ -proteobacterial homologs, this region contains either an additional α -helix that is
189 known to have important function in the transfer of lipoprotein cargo (27), or flexible loops that would both
190 clash with the PEG molecule. Finally, superimposition of LolA_{Bb}-SA and LolA_{Bb}-PEG and the recently
191 solved liganded *E. coli* LolA-Pal₁₃ lipopeptide complex (28) (7Z6W) yielded an RMSD of 2.44 Å between
192 C α atoms (136 residues) and confirmed that the PEG and SA molecules bind at the site that is functionally
193 occupied in *E. coli* LolA by the Pal₁₃ lipopeptide (**Supplemental materials Fig. S6B**). Intriguingly, *E. coli*
194 LolB (1IWN) also has a reported PEG fragment bound to the core of the protein. Superimposition of LolB
195 with LolA_{Bb} yielded an RMSD deviation of 2.84 Å for 127 aligned residues. As shown in **Fig. 4**, the
196 structures are similar, but they contain displaced secondary structure elements relative to one another,
197 including an additional α -helix that would clash with the PEG molecule in LolA_{Bb}, as already noted for
198 some of the γ -proteobacterial LolAs. Notably, the PEG molecules in LolB and LolA_{Bb}-PEG adopt similar
199 binding modes (**Fig. 4B**). However, the PEG molecule in LolA_{Bb}-PEG is a larger fragment which requires
200 displacement of the loop between β 6 and α 2 for binding.

201 In addition to the absence of an α -helix, rotation of the four structure overlays shown in **Fig. 3**
202 reveals another significant difference between LolA_{Bb}-PEG and other solved homologs (**Fig. 5**). More
203 specifically, LolA_{Bb}-PEG has a 15 amino acid flexible loop spanning residues T102 to G116 that replaces
204 a turn between antiparallel β -sheets 7 and 8 in the γ -proteobacterial LolA homologs. This solvent-exposed
205 flexible loop contains two hydrophobic leucine residues (L107 and L110) near the loop's center point with
206 predicted salt bridging from D111 to the backbone's R148 and R159 residues. Together, L110, D111,
207 R148, and R149 compose 4 of the most highly conserved residues among 150 diverse spirochetal
208 homologs including those found within Lyme disease and relapsing fever-causing *Borreliaceae*, syphilis
209 and periodontal disease-causing *Treponemataceae*, and other environmental spirochetes
210 (**Supplemental Data Fig. S7**). Intriguingly, LolB from *E. coli* has a similar hydrophobic residue-
211 containing loop that is responsible for inserting lipoproteins into the periplasmic leaflet of the OM with its
212 central L68 residue (20). However, the LolB loop is composed of only five amino acids and is located at
213 the opposite end of LolB when the structures are superimposed (**Fig. 4**).

214

215 **LolA_{Bb} is essential for *B. burgdorferi* growth.** To investigate whether LolA_{Bb} is required for growth, we
216 used a conditional *lolA* knockout strain of *B. burgdorferi* 297. In this recombinant strain, a kanamycin
217 resistance cassette was used to disrupt the chromosomal copy of BB_0346 while expressing an ectopic
218 plasmid-encoded allele under an IPTG-inducible P_{pQE30} promoter. As shown in **Fig. 6A**, removal of IPTG
219 driving the expression LolA_{Bb} led to a marked growth defect within 48 hours. By day 2 post-IPTG removal,
220 we observed pleomorphic abnormalities that ranged from blebbing along the cell length to full rounding
221 of some cells, suggesting severe structural deficiencies in the cell envelope (**Fig. 6B**). At day 1 post-
222 depletion, we detected an approximate 10-fold reduction in LolA_{Bb} protein levels compared to w.t. cells
223 (**Fig. 6D**). This was concomitant with a 12-fold reduction in BB_0346 transcript levels, as measured by
224 RT-qPCR (data not shown).

225

226 **LolA_{Bb} depletion does not affect surface lipoprotein secretion but leads to emerging**
227 **mislocalization of IM lipoproteins to the OM.** The observed delay between LolA_{Bb} depletion and
228 phenotypic changes was likely a consequence of envelope homeostasis mediated by residual, properly
229 localized lipoproteins. To observe nascent surface lipoprotein secretion under LolA_{Bb}-depleted
230 conditions, we modified our standard proteinase K (PK) surface localization assay (29) by adding a “pre-
231 shaving” step. Briefly, cells cultured under LolA_{Bb}-depleting and control conditions for 24 hours (at the
232 day 1 timepoint) were washed and treated with PK for 1 hour to remove accessible surface-localized
233 proteins. After a 4-hour recovery in fresh culture medium under depleting or non-depleting conditions,
234 the cells were again washed and then “re-shaved” with PK (**Fig. 6C**). Western immunoblot analysis of
235 the resulting samples showed that LolA_{Bb}-depleted cells maintained their ability to secrete the prototypical
236 outer surface lipoprotein OspA, presumably using a reconfigured Lpt transport system in *Borrelia*
237 *burgdorferi* (4). At the same time, periplasmic IM lipoprotein OppAIV and OM lipoprotein Lp6.6, as well
238 as the periplasmic flagellar protein FlaB, remained inaccessible to PK, indicating that they remained
239 periplasmic and that there was no major disruption of the OM barrier at this timepoint. (**Fig. 6E**).

240 To further characterize the broader consequences of LolA_{Bb} depletion on OM lipoprotein transport,
241 we next used a cell fractionation assay to separate and purify outer membrane vesicles (OMVs) from a
242 protoplasmic cylinder (PC) fraction (30); note that the PC fraction also contains remaining intact cells. As
243 expected from the PK shaving assays, there was no apparent defect in OspA transport to the OM under
244 LolA_{Bb}-depleting conditions. To our surprise, however, there was also no detectable change in Lp6.6
245 abundance in the OM, but OppAIV became significantly mislocalized to the OM (**Fig. 6F**).

246 To exclude the possibility of OMV contamination by IM proteins, and at the same time gain a more
247 comprehensive view of the effect of LolA_{Bb} depletion on the OM proteome, we analyzed the PC and OMV
248 cell fractions by Multidimensional Protein Identification Technology (MudPIT) label free quantitative mass
249 spectrometry, as used in our previous studies of the *B. burgdorferi* envelope (4, 5). Based on the obtained
250 distributed Normalized Spectral Abundance Factor (dNSAF) values, we were able to derive the

251 abundance of each protein in each cell fraction. To calculate a dNSAF ratio illustrating abundance
252 changes in the OM proteome, we then divided the OMV dNSAF values for each protein under LolA_{Bb}-
253 depleted conditions by those under control (“LolA_{Bb}-replete”) conditions. Only proteins that were detected
254 in at least 2 out of the 3 biological replicates were included in the analysis.

255 These data illustrated several points. First, they showed that the OMV fractions obtained on day
256 1 retained high OM-specific purity even with LolA_{Bb} depletion: non-lipoprotein IM controls such as
257 secretory machinery proteins SecY, SecE, SecF and SecD, post-translational lipoprotein modification
258 pathway proteins Lgt and Lnt, as well as LolD were readily detected in the PC fractions but remained
259 undetectable in the OMV fractions (**Fig. 7**). Second, they further supported the intriguing OppAIV
260 immunoblot results, as 6 of the 17 detected IM lipoproteins (including OppAIV) showed a statistically
261 significant increase in OMV fraction abundance under LolA_{Bb} depletion conditions (**Fig. 8**), mostly above
262 a mean 1.5-fold change. At the same time, only 3 of 24 detected surface lipoproteins were significantly
263 reduced in the OMV fraction with LolA_{Bb} depletion, and their mean fold changes remained below 1.5-fold,
264 confirming the OspA immunoblot data. Interestingly, the 6 detected periplasmic OM lipoproteins showed
265 an almost even split between increased, decreased, and unchanged abundance: Lp6.6 and BB0323
266 increased significantly in abundance in the OMV fraction, whereas BamB and BB0460 dropped in
267 abundance. Notably, there was no change in the OM abundance of BamD at this timepoint. All proteins
268 with specific changes in abundance in the PC and OMV fractions are listed in **Supplemental Data Tables**
269 **S2 and S3**, respectively.

270 To potentially demonstrate a more severe lipoprotein mislocalization phenotype, we attempted to
271 characterize envelope fractions from cells that had been LolA_{Bb}-depleted for 48 hours (day 2 timepoint).
272 However, at this point, cell envelopes were apparently too disturbed (see **Fig. 6B**) to be successfully
273 fractionated, resulting in OMV fractions that were indistinguishable in protein content from PC fractions
274 when analyzed by SDS-PAGE (**Supplemental Data Fig. S8**).

275

276

277 **DISCUSSION**

278 Efficient and accurate lipoprotein localization is essential for survival in diderm bacteria, as lipoproteins
279 mediate a wide variety of important cellular functions, including the assembly and function of essential
280 outer membrane machinery like the Bam complex (1). Like α -, δ -, and ϵ -proteobacteria, *B. burgdorferi*
281 has all the canonical Lol pathway components found in *E. coli* except for an identified LolB outer
282 membrane lipoprotein acceptor. Here, we solved the crystal structure of the *B. burgdorferi* LolA homolog
283 BB0346 (LolA_{Bb}) in both PEG and steric acid bound forms to 1.9 Å and 1.8 Å resolution, respectively. In
284 these structures, we identified two unique LolA_{Bb} loop domains with comparative analyses to other solved
285 LolA structures.

286 The first loop replaces an entire α -helix (α 2) that typically protrudes into the hydrophobic core of
287 canonical LolA homologs to facilitate cargo acceptance from LolC at the IM and transfer to LolB at the
288 OM (27) (**Fig. 3**). This loop appears to provide increased flexibility over the α -helix, since it is fully
289 displaced out of the protein's core to accommodate binding of a PEG molecule fragment or steric acid.
290 Curiously, AlphaFold (AF-O51321-F1) predicts this loop is also displaced out of the core in the absence
291 of ligand, providing a fairly accurate prediction that differs from the solved LolA_{Bb}-PEG structure (7TPM)
292 by an RMSD of 1.077 Å. The second loop extends a turn between antiparallel β -sheets 7 and 8 near the
293 N-terminus of LolA_{Bb} (**Fig. 5**), bearing some resemblance to a LolB loop that is involved in lipoprotein
294 insertion into the outer membrane (20) (**Fig. 4**). Recently, Smith and colleagues identified a “bifunctional”
295 LolA homolog (LolA_{Cv}) from the also LolB-deficient α -proteobacterium *Caulobacter vibrioides* (23). LolA_{Cv}
296 was modeled *in silico* to also have an extended loop between antiparallel β -sheets 7 and 8 (loop β 7- β 8),
297 and this loop was experimentally linked to the protein's ability to insert lipoproteins into the OM by
298 replacing LolA and LolB in *E. coli* with heterologously expressed LolA_{Cv} (23). Notably, deletion or
299 substitution of L119 near the center point of loop β 7- β 8 in LolA_{Cv} eliminated its ability to complement *E.*
300 *coli* LolB. This suggests that the corresponding crystal structure-confirmed loop β 7- β 8 in LolA_{Bb} provides
301 a similar LolB-like lipoprotein insertase function. Of note, the positively charged C-terminus of LolA_{Cv} had
302 to be modified to allow for interaction with the periplasmic pad of *E. coli* LolC (23). In this study, a similarly

303 modified LolA_{Bb} chimera failed to complement *E. coli* LolA (**Fig. 1; Supplemental Fig. S2**), suggesting
304 that the spirochetal LolA homolog might function differently still.

305 There are several potential explanations for why chimeric LolA_{Bb} was unable to complement the
306 *E. coli* LolA conditional knockout strain despite its correct localization to the periplasmic space and C-
307 terminal alteration for permitting interaction with the LolCDE complex in *E. coli*. For example, the
308 replacement of the canonical LolA α 2-helix by a flexible loop in *B. burgdorferi*, and potentially all
309 *Borreliaceae* homologs, may lead to incompatibility between proteobacterial and spirochetal Lol systems
310 in both the lipoprotein acceptance and release steps. Another possible explanation is rooted in the
311 different phospholipid compositions of *E. coli* and *B. burgdorferi*. Just as phospholipid composition was
312 shown to be important for extrusion of lipoproteins from the inner membrane by LolE (16), a soluble form
313 of LolB (denoted mLolB) was able to insert lipoproteins into synthetic liposomes in a phospholipid
314 composition-dependent manner (31). The particularly phosphatidylcholine-rich membranes of *Borrelia*
315 may therefore be required for LolA_{Bb} insertase function. Finally, our experiments with a *B. burgdorferi*
316 conditional knockout strain resulted in unexpected mislocalization of IM lipoproteins to the outer
317 membrane under LolA_{Bb} depletion conditions (**Figs. 8 and 9**). One possible explanation for this
318 phenotype might be that disruption of the Lol pathway leads to an accumulation of lipoproteins in the IM,
319 which are then indiscriminately force-fed to the otherwise surface lipoprotein-transporting Lpt pathway to
320 alleviate IM stress. As we didn't observe sudden surface exposure of periplasmic OM lipoproteins under
321 those conditions, this would require ejection of natively non-surface lipoproteins from the Lpt pathway at
322 the periplasmic face of the OM. Another, even more intriguing explanation would be that the *B. burgdorferi*
323 Lol pathway works not only in the canonical anterograde direction but can also remove mislocalized
324 lipoproteins from the OM and return them to the IM in a retrograde step, reminiscent of the proteobacterial
325 Mla (maintenance of OM lipid asymmetry) system removing misplaced phospholipids from the surface
326 leaflet of the proteobacterial OM and transporting them back to the IM (32, 33).

327 More detailed studies will be needed to investigate the operational directionality and precise
328 structure-function of LolA_{Bb} in its native system, since our current observations suggest that the

329 evolutionary distance between spirochetes and proteobacteria may have resulted in diverse Lol system
330 modalities. Such was the case for the *B. burgdorferi* BB0838 homolog of LptD that, rather than
331 transporting lipidated polysaccharides, was shown to be required for the translocation of lipidated proteins
332 to the LPS-deficient cell surface of *Borrelia* (4). In support of this previous finding, we have now observed
333 that LolA_{Bb} plays no direct role in the transport of surface lipoproteins, as depletion of LolA_{Bb}, unlike
334 depletion of LptD_{Bb}, had little to no immediate effect on the proper localization of OspA and other surface
335 lipoproteins. This further supports our earlier proposed model of two dichotomous lipoprotein pathways
336 in *Borrelia* spirochetes (4): (i) a pathogenesis-associated Lpt pathway that ensures rapid deployment of
337 crucial surface lipoprotein virulence factors required for efficient vector-borne transmission,
338 dissemination, and persistent infection of vectors and reservoir hosts, and (ii) a “house-keeping” Lol
339 pathway that ensures proper lipoprotein localization and homeostasis within the periplasm. Specific
340 mechanistic details on both transport pathways have yet to be elucidated, including the possibility for
341 some collaborative crosstalk between them. Since both systems are essential but composed from
342 modular components that diverge structurally and functionally from those found in other model diderms,
343 their continued study will further highlight the diversity of microbial envelope biogenesis systems and
344 potentially lead to the discovery of narrow-spectrum therapeutics.

345

346 **MATERIALS & METHODS**

347 **Strains and growth conditions.** Chemically competent NEB[®] 5-alpha F'Iq cells (NEB; C2992H) were
348 transformed with recombinant plasmids per manufacturer instructions and grown at 37°C on selective
349 Luria-Bertani (LB) agar plates (BD; 244520) and in LB broth (Fisher; BP1426). Plasmid DNA was isolated
350 from *E. coli* clones using a Miniprep kit (Macherey-Nagel; 740588) and verified by Oxford Nanopore
351 Technology sequencing (Plasmidsaurus) or single-pass primer extension sequencing (ACGT, Inc.) with
352 DNA oligonucleotide primers (Integrated DNA Technologies). Verified plasmids were then used to
353 transform *E. coli* or *B. burgdorferi* strains as specified. The *E. coli* TT011 conditional knockout of *lolA* was

354 kindly provided by Hajime Tokuda ((22); Institute of Molecular and Cellular Biosciences, University of
355 Tokyo, Tokyo, Japan).

356 *B. burgdorferi* strains B31 and 297 and their recombinant derivatives were grown at 34°C under
357 5% CO₂ in sterile filtered Barbour-Stonner-Kelly-II (BSK-II) medium containing 9.7 g/L CMRL-1066 (US
358 Biological, C5900-01), 5.0 g/L neopeptone (Gibco, 211681), 6.6 g/L HEPES sodium salt (Fisher, BP410),
359 0.7 g/L citric acid (Sigma, C-8532), 5.0 g/L dextrose anhydrous (Fisher, BP350), 2.0 g/L yeastolate
360 (Gibco, 255772), 2.2 g/L sodium bicarbonate (Fisher, BP328), 0.8 g/L sodium pyruvate (Fisher,
361 AC132155000), 0.4 g/L *N*-acetylglucosamine (Sigma, A3286), 25 mg/L phenol red (Sigma, P-3532), and
362 50.0 g/L bovine serum albumin (Gemini, 700-104P) at pH 7.6-7.7, with 60 mL/L heat-inactivated rabbit
363 serum (Pel Freez, 31126), and 200 mL/L 7% gelatin (Gibco, 214340) added before use. Streptomycin
364 was added to BSK-II at a final concentration of 100 µg/mL for selection of *B. burgdorferi* strains containing
365 IPTG-inducible plasmids.

366

367 **Recombinant plasmids.** Recombinant plasmids were produced by a combination of classical
368 subcloning, gene splicing by overlap extension (SOEing), site-directed mutagenesis (SDM), and DNA
369 fragment synthesis through Twist Bioscience. For plasmid maps and sequences, see **Supplemental**
370 **Materials and Methods**). To simplify the cloning of genes under an IPTG-inducible P_{pQE30} promoter for
371 controlled expression in both *E. coli* and *B. burgdorferi*, we modified pJSB104 (34) by removing an
372 extraneous NdeI site in the plasmid's backbone via SDM with primers Nde-aadA_F (5'-
373 GAGGTTTCCAGATGAGGGAAGCGGTGATC-3') and Nde-aadA_R (5'-
374 CTTCCCTCATCTGGAAACCTCCCTCATTTAAAATTG-3'). Fusions of either the *E. coli* or *B. burgdorferi*
375 signal peptide sequence I (SSI) to superfolder GFP (sfGFP) or the mature region of BB0346 with a C-
376 terminal FLAG tag (mLoIA_{Bb}-FLAG) were then restriction-ligated into the modified pJSB104, resulting in
377 expression plasmids for SSI_{Ec}-sfGFP, SSI_{Bb}-sfGFP, SSI_{Ec}-mLoIA_{Bb}-FLAG, or SSI_{Bb}-mLoIA_{Bb}-FLAG.
378 Spectinomycin was added to LB and LB agar at a final concentration of 100 µg/mL for the maintenance
379 of all IPTG-inducible plasmids in *E. coli*.

380 pBAD33 (35) (provided by Joe Lutkenhaus, University of Kansas Medical Center) was used for
381 arabinose-inducible expression of genes in the *lolA* conditional knockout *E. coli* strain. First, an untagged
382 *E. coli* codon-optimized SSI_{Ec}-mLolA_{Bb} was synthesized by and subcloned into pBAD33 using
383 SacI/HindIII restriction and ligation. Next, an upstream Shine–Dalgarno sequence from bacteriophage T7
384 gene 10 (36) was inserted via site directed mutagenesis with phosphorylated primers pBAD_RBS_F (5'-
385 TTAAGAAGGAGATCGAGCTCATGAAAAAATAGC-3') and pBAD_RBS_R (5'-
386 AGTTAAACAAAATTATTTCTAGCCCAAAAAACGGG -3'). This plasmid was then modified for SPI_{Ec}-
387 mLolA_{BbCOChim} chimera expression by inserting a synthesized fragment digested with BglIII and HindIII into
388 the downstream region. Finally, the LolA_{Ec} expression vector was generated by replacing SPI_{Ec}-
389 mLolA_{BbCO} with a synthesized *lolA* gene from *Escherichia coli* str. K-12 substr. MG1655 via SacI/HindIII
390 subcloning. Chloramphenicol was added to LB and LB agar at a final concentration of 34 µg/mL for the
391 maintenance of all arabinose-inducible plasmids in *E. coli*.

392

393 **Transformation and clonal selection of *B. burgdorferi*.** Electrocompetent B31-e2 or 297 cells were
394 transformed by electroporation (37) with 500 ng to 5 µg of plasmid in 2-mm gap cuvettes (Thermo
395 Scientific; 5520) using a Bio-Rad MicroPulser on EC2 setting, consistently measuring 2.49-kV/cm field
396 strength and approximately 5-ms pulse times. Electroporated cells were immediately resuspended in
397 12 mL of prewarmed BSK-II and allowed to recover at 34°C for 18 to 20 h. Clonal selection of
398 transformants was carried out by adding the 12 mL recovered culture to 35 mL selective BSK-II, followed
399 by plating into 96-well microtiter plates and 8 to 16 days of incubation (38). Culture-positive wells were
400 expanded into 6 mL of selective BSK-II and allowed to reach stationary phase for verification of plasmid
401 acquisition by direct PCR of cultured *B. burgdorferi* cells using QuickLoad 2× Taq Master Mix (NEB,
402 M0271). Positive clones were flash frozen on dry ice in BSK-II containing 10% DMSO (Sigma; D2438)
403 and stored at -80°C.

404

405 **Recombinant *B. burgdorferi* strains.** The *B. burgdorferi* conditional *bb_0346/lolA_{Bb}* knockout was
406 generated using a merodiploid intermediate. Endogenous plasmid contents of all clones were confirmed
407 by PCR-based plasmid profiling (39), and only clones with profiles comparable to the strain 297 parent
408 were used (data not shown). The BB_0346 ORF was amplified by PCR with flanking NdeI and HindIII
409 sites; 5' BB0346-NdeI (5'-GAGTTGGACATATGATAAAAACAATAC-3') and 3' BB0346-HindIII 5'-
410 CATTTTCTTTCATAGATTGGAAGCTTAATTTTTTTTAA-3'). An internal HindIII site in *bb_0346* was
411 removed by silent mutation using PCR SOEing; 5' BB0346 int-HindIII (5'-
412 AACCTTTTCTAGAAAACCTTTACAAGGG-3') and 3' BB0346 int-HindIII (5'-
413 CCCTTGTAAGTTTTCTAGAAAAGGTT-3'). This NdeI/HindIII fragment was then inserted into a
414 pJSB104 (34) derivative conferring streptomycin resistance, resulting in piBB0346. piBB0346 was
415 electroporated into *B. burgdorferi* strain 297, yielding recombinant strain FF2. Plasmid recovery in *E. coli*
416 was used to confirm the presence of piBB0346 in streptomycin-resistant transformants. Next, a pGEM-T
417 Easy-based plasmid was used to disrupt the chromosomal copy of *bb_0346*. Regions upstream and
418 downstream of the ORF were amplified by PCR using primers 5' F1 bb0346 (5'-
419 GAATATAGGGTAAGATAATTGCTGCTCGGC-3'), 3' F1 bb0346-AscI (5'-
420 gGcGcGCcGCTACTATTAATTCTTTTATTATTGCTTTTGC-3'), 5' F2 bb0346-AscI (5'-
421 ggcgcGCcGATATTTGAGAAAACACAACAACAGG-3'), and 3' F2 bb0346-BssHII (5'-
422 gcgcgcTGCCCTTTTTATATGCTTTAAAATATTGCAAGGC-3'), TA cloned and ligated with an AscI-
423 flanked *aph[3']-IIIa* kanamycin resistance marker (40) at the junction of the two fragments. This resulted
424 in replacement of an internal 382-bp region of the *bb_0346* with the *aph[3']-IIIa* marker, leaving 59 bp of
425 the 5' end ORF and 210 bp of the 3' end of the ORF. The resulting mutation construct, designated pGEM-
426 *bb0346::aph[3']-IIIa*, was used to transform recombinant strain FF2. Transformants were selected with
427 streptomycin/kanamycin and grown in BSK-II supplemented with 1 mM IPTG to maintain *bb_0346*
428 expression. The presence of piBB0346 in two kanamycin/streptomycin-resistant clones, FH2 and FH4,
429 was confirmed by plasmid recovery, and PCR was used to confirm disruption of the chromosomal copy

430 of *bb_0346* by the *aph[3']-IIIa* marker. The resulting chromosomal locus is shown in **Supplemental**
431 **Materials Fig. S10.**

432

433 **RT-qPCR for transcription expression analysis.** Total RNA was extracted from *B. burgdorferi* cell
434 pellets with TRIzol Reagent (Invitrogen; 15596026) according to the manufacturer's instructions after a
435 30-minute 3,000 × *g* swinging-bucket centrifugation at room temperature. Residual DNA contamination
436 was removed by a 1-hour DNase I treatment (Thermo Scientific; 18047019) followed by phenol-
437 chloroform extraction (Ambion; AM9720) and standard ammonium acetate/ethanol precipitation (41).
438 RNA samples were used for reverse transcription and quantification of BB_0345, BB_0346, BB_0347,
439 and *flaB* rRNA transcripts by the Luna Universal one-step RT-qPCR kit (NEB, E3005), according to the
440 manufacturer's instructions, on an Applied Biosystems 7500 Fast real-time PCR system. The primer sets
441 for amplification were BorFlaLeo-R-ok (5'-GCTGGTGTGTTAATTTTTGCAG-3') + FlaW-sense4 (5'-
442 AGCAACTTACAGACGAAATTAATAG-3') (42), 0345_F (5'-AAACCCTGAGGGGGTCTTTA-3') +
443 0345_R (5'-GGGAAGTCTCTTTTTGCATCC-3'), 0346_F (5'-GACCTCCCCCACTACTACC-3') + 0346_R
444 (5'-ATAGAGGACATGCAAGCAAC-3'), and 0347_F (5'-ACCAAAGAAAATGCCTTGC-3') + 0347_R (5'-
445 CAAGCCTATTTTTGGCGTTT-3'). Transcript levels were validated and normalized against *flaB*
446 endogenous control transcript with fold changes calculated using the comparative CT (2^{-ΔΔCT}) method
447 for quantification.

448

449 **Recombinant protein expression.** The sequence encoding mature *B. burgdorferi* LolA without a signal
450 peptide was amplified by PCR from *B. burgdorferi* strain B31 genomic DNA (*BB_0346* ORF) using
451 oligonucleotide primers Nde_Q18BbloIA_F (5'-GGAATTCATATGCAAATATCTGCAAATC-3') and
452 Xho_BbloIA_R (5'-CCGCTCGAGATTTTTTTTAATATCAT-3'). This amplicon was NdeI/XhoI restricted
453 and T4 ligated into pET29b(+) expression vector, resulting in pET29b:mlolA-his. After confirmatory
454 sequencing of the insert and flanking regions, the plasmid was transformed into *E. coli* BL21(DE3)pLysS
455 chemically competent cells (Invitrogen, C606003) per manufacture instructions. A single transformant

456 colony on LB agar containing 30 µg/mL kanamycin and 34 µg/mL chloramphenicol was grown overnight
457 in 5mL of selective LB broth with shaking at 37 °C. This starter culture was diluted 1:50 in 1000 mL of
458 selective LB broth and cultured with shaking at 37 °C until an OD₆₀₀ of 0.5. At this point, recombinant
459 protein expression was induced by the addition of IPTG (1 mM final), and incubation was continued for 3
460 hours. Next, the cells were harvested by centrifugation in a Sorvall RC 6 Plus for 20 min at 5,000 rpm
461 (~4,400 x g). Cell pellets were resuspended to a total volume of 200 mL in cobalt column binding buffer
462 (50mM NaPO₄, 300mM NaCl, pH7.4) and frozen at -80°C overnight. After thawing on ice, the
463 resuspended cells were finally lysed with 2 passages through a French press, and the resulting clarified
464 lysate was centrifuged at 10,000 x g for 30 min to collect supernatant containing the soluble protein of
465 interest.

466

467 **IMAC and ion exchange FPLC.** To purify mature hexahistidine-tagged BB0346 (LolA_{Bb}), the soluble
468 lysate was passed through a 0.45 µm sterile filter for loading onto a binding buffer equilibrated HiTrap
469 TALON column via the ÄKTA start protein purification system. After the sample was applied to the
470 column, 15 column volumes (CVs) of 96.7% binding buffer and 3.3% elution buffer (50mM NaPO₄,
471 300mM NaCl, 150mM imidazole, pH7.4) were used to wash out unbound protein. Linear gradient elution
472 began with 3.3% elution buffer and ended with 100% elution buffer to obtain an ultraviolet eluent peak
473 between 27% and 63% elution buffer. The collected peak fractions were placed into a 3000 NMWL
474 centrifugal filter unit and concentrated until approximately 1mL of purified sample remained. For
475 subsequent cation exchange chromatography, concentrated affinity column eluent was mixed with 14mL
476 of exchange buffer (50mM MES, pH 5.6), and 4mL of the resulting sample was loaded onto an exchange
477 buffer equilibrated HiTrap SP HP column. After the sample was applied to the column, 15 CVs of
478 exchange buffer were used to wash out any unbound protein. Linear gradient elution proceeded from 0%
479 to 100% ionic elution buffer (50mM MES, 1M NaCl, pH 5.6) with an ultraviolet eluent peak between 38%
480 and 50% ionic elution buffer. A final round of TALON column purification was performed to help eliminate
481 any remaining impurities and to concentrate the protein.

482

483 **Crystallization and data collection.** Purified LolA_{Bb} containing a C-terminal His-tag was concentrated
484 to 10 mg/mL in 450 mM NaCl, 50 mM MES pH 5.6, 10% glycerol for crystallization screening. All
485 crystallization experiments were set up using an NT8 drop setting robot (Formulatrix Inc.) and UVXPO
486 MRC (Molecular Dimensions) sitting drop vapor diffusion plates at 18 °C. 100 nL protein and 100 nL
487 crystallization solution were dispensed and equilibrated against 50 µL of the crystallization solution.
488 Crystals of LolA_{Bb}-PEG were observed after 2 weeks from various conditions in the Berkeley Screen (43)
489 (Rigaku Reagents). A cryoprotectant solution composed of 80% crystallization solution and 20% glycerol
490 was dispensed (2 µL) onto the drop, and crystals were harvested immediately and stored in liquid
491 nitrogen. Crystals used to prepare iodine heavy atom derivatives were obtained from condition F6 (2 M
492 sodium formate, 100 mM HEPES pH 7.5, 5% (w/v) PEG 5000 MME). A solution containing 6.5 µL of
493 crystallant F6, 1.5 µL of 1M potassium iodide (150mM) and 2µL of glycerol was layered onto the drop
494 containing crystals and incubated for 2 minutes. Samples were harvested directly and stored in liquid
495 nitrogen. Crystals of LolA_{Bb}-SA were obtained from Berkeley condition E4 (1500 mM Ammonium sulfate,
496 100 mM Hepes pH 7.5) and samples were cryoprotected with 2.5M lithium sulfate layered onto the drop.
497 X-ray diffraction data for LolA_{Bb}-PEG were collected at the Advanced Photon Source beamline 17-ID
498 (IMCA-CAT) and LolA_{Bb}-SA crystals were examined at the National Synchrotron Light Source II (NSLS-
499 II) NYX beamline 19-ID. Native data for LolA_{Bb}-PEG were collected using crystals from condition F4 at
500 $\lambda=1.0000$ Å. Data for the crystals soaked in the presence of potassium iodide from condition F6 were
501 collected at $\lambda=1.7463$ Å.

502

503 **Structure solution and refinement.** Intensities were integrated using XDS (44, 45) via Autoproc (46)
504 and the Laue class analysis and data scaling were performed with Aimless(47). Structure solution was
505 conducted by SAD phasing with Crank2 (48) using the Shelx (49), Refmac (50), Solomon (51), Parrot
506 (52) and Buccaneer (53) pipeline via the CCP4 (54) interface. Six iodide sites were located with
507 occupancies greater than 0.20 and phasing/density modification resulted in a mean figure of merit of 0.58

508 in the space group $P4_132$. Subsequent model building utilizing density modification and phased
509 refinement yielded $R/R_{\text{free}} = 0.262/0.294$ for the initial model. This model was used for molecular
510 replacement with Phaser (55) against the higher resolution native data set and the top solution was
511 obtained for a single molecule of LolA_{Bb} in the asymmetric unit in the space group $P4_132$ (RFZ=3.7,
512 TFZ=82.9, LLG=8408). Additional refinement and manual model building were conducted with Phenix
513 and Coot (56) respectively. Disordered side chains were truncated to the point for which electron density
514 could be observed. Structure validation was conducted with Molprobit (57) and figures were prepared
515 using the CCP4MG package (58). Crystallographic data are provided in **Supplemental Table S1**.

516

517 **Growth curves.** Cultures of the *B. burgdorferi* 297 conditional knockout strain were inoculated at 1×10^5
518 cells/mL in selective BSK-II media with various IPTG concentrations. At 24-hour intervals over a 4-day
519 period, cell density was assessed by direct counting of bacterial cultures diluted 2- to 100-fold in PBS
520 using a Petroff Hauser counting chamber under a phase-contrast microscope (Nikon Eclipse E400).

521

522 **PK recovery assay for nascent surface lipoprotein transport analysis.** After 24 hours with or without
523 0.1mM IPTG induction of BB0346/LolA_{Bb} expression, 250 mL of late-log spirochetes were harvested at
524 3,000 x *g* for 30 minutes. The resulting cell pellets were gently washed with 40 mL of Dulbecco's
525 phosphate buffered saline with 5mM MgSO₄ (dPBS+Mg) to remove culture medium BSA and re-pelleted
526 at 3,000 x *g* for 10 minutes. Next, the washed cell pellets were gently resuspended in 12.5 mL of
527 dPBS+Mg, and the resuspensions were split into two separate 6 mL aliquots. To one aliquot from each
528 condition (cells grown with or without IPTG), 250 μ L of milliQ water was added as a control. To the second
529 aliquot from each condition, 250 μ L of 5 mg/mL proteinase K (PK) in milliQ water was added for a final
530 concentration of 200 μ g/mL PK. Samples were nutated at room temperature for 45 minutes on the lowest
531 possible speed (approximately 5 rpm). After the incubation, each sample was added to separate 50 mL
532 conical tubes containing 30 mL of dPBS with 5% BSA. The tubes were inverted for mixing, and cells were
533 re-pelleted at 3,000 x *g* for 10 minutes. Resulting cell pellets were gently resuspended in 45mL of

534 selective BSK-II media with or without 0.1mM IPTG, matching the condition they were previously grown
535 in. After a 4-hour recovery incubation at 34°C with 5% CO₂, the previous steps were repeated for a
536 second round of PK treatment. Specifically, each 45mL culture was harvested at 3,000 x g for 30 minutes.
537 The resulting cell pellets were gently washed with 20 mL of BSA-stripping buffer and re-pelleted at 3,000
538 x g for 10 minutes. Next, the washed cell pellets were gently resuspended in 3.125 mL of dPBS+Mg, and
539 the resuspensions were split into two separate 1.5 mL aliquots. To one aliquot from each condition (cells
540 grown with or without IPTG, with or without an initial round of shaving), 62.5 µL of milliQ water was added
541 as a control. To the second aliquot from each condition, 62.5 µL of 5 mg/mL proteinase K (PK) in milliQ
542 water was added for a final concentration of 200 µg/mL PK. Samples were nutated at room temperature
543 for 45 minutes on the lowest possible speed. To each aliquot of cells, 8.25 µL of 1M PMSF protease
544 inhibitor was added for a final concentration of 5 mM PMSF. Finally, the cells were pelleted at 16,000 x
545 g for 10 minutes and resuspended in 1x SDS Sample Buffer for analysis by Coomassie-stained SDS-
546 PAGE and Western immunoblots.

547

548 **Hypotonic citrate fractionation for outer membrane analysis.** OMVs were isolated as previously
549 described (30). Briefly, cultures were harvested and washed with dPBS containing 0.1% (wt/vol) BSA.
550 Cells were then resuspended in 25 mM sodium citrate (pH 3.2) containing 0.1% (wt/vol) BSA. Cell
551 suspensions were shaken for 2 hours at room temperature in a New Brunswick C24 incubator at 250 rpm
552 to release OMVs. After this agitation period, the cell suspensions were harvested, resuspended in citrate
553 buffer containing BSA, and loaded onto a discontinuous 56%-42%-25% (wt/wt) sucrose gradients
554 prepared in Beckman UltraClear tubes. The gradients were centrifuged at 120,000 × g for 18 hours at
555 4°C in a Beckman Coulter XPN-80 ultracentrifuge using an SW 32 Ti rotor, and the resulting upper outer
556 membrane vesicle (OMV) bands and lower protoplasmic cylinder (PC) bands were extracted by needle
557 aspiration. Fractions were diluted in cold dPBS, re-pelleted separately, and then resuspended in dPBS
558 containing 1 mM PMSF. A portion of the resuspended fractions was used to prepare SDS-PAGEs and
559 western immunoblots, and the remainder was stored at -80°C for later analysis.

560

561 **Genomic sequencing of *B. burgdorferi* 297.** Hybrid Oxford Nanopore Technology (ONT) and Illumina
562 short read sequencing was performed by SeqCenter (Pittsburgh, PA) on genomic DNA isolated from *B.*
563 *burgdorferi* strain 297 with a Quick-DNA Miniprep Plus Kit (Zymogen, D4068). Specifically, Illumina
564 sequencing libraries were prepared using the tagmentation-based and PCR-based Illumina DNA Prep kit
565 and custom IDT 10bp unique dual indices (UDI) with a target insert size of 320 bp. No additional DNA
566 fragmentation or size selection steps were performed. Illumina sequencing was performed on an Illumina
567 NovaSeq 6000 sequencer in one or more multiplexed shared-flow-cell runs, producing 2 x 151bp paired-
568 end reads. Demultiplexing, quality control and adapter trimming was performed with bcl-convert1 (v4.1.5).
569 Nanopore sequencing was performed on an Oxford Nanopore a MinION Mk1B sequencer or a GridION
570 sequencer using R10.4.1 flow cells in one or more multiplexed shared-flow-cell runs. Run design utilized
571 the 400bps sequencing mode with a minimum read length of 200 bp. Adaptive sampling was not enabled.
572 Guppy1 (v6.4.6) was used for super-accurate basecalling (SUP), demultiplexing, and adapter removal.

573

574 **Assembly and annotation of *B. burgdorferi* strain 297 genomic sequencing data.** ONT and Illumina
575 reads were *de novo* assembled using a combination of Tricycler long-read assembly, Medaka long-read
576 polishing, and Polypolish short-read polishing, as described by Wick and colleagues (59). The main linear
577 chromosome (965,079 bp) and circular plasmid cp26 (26,514 bp) were identified from the resulting
578 assembled contigs, with cp26 having 100% sequence identity to a previously deposited strain 297 cp26
579 sequence (Genbank accession number CP002268.1) (60).

580 11 kb and 33 kb reverse complement (i.e. inverted repeat) sequences flanking both ends of the
581 large linear chromosome were manually removed from the assembly. These sequencing artifacts arose
582 from the covalently closed hairpin telomeres of linear genomic elements in *B. burgdorferi* (61). Because
583 the smaller plasmid elements proved challenging to assemble *de novo* with high confidence, a hybrid
584 FASTA file was generated, combining the new linear chromosome sequence with all 20 strain 297
585 plasmid sequences previously assembled by Schutzer and colleagues (60). This FASTA file was run

586 through the National Center for Biotechnology Information (NCBI) Prokaryotic Genome Annotation
587 Pipeline (PGAP), and arbitrary locus tags (e.g. pgaptmp_000001) were replaced with known *B.*
588 *burgdorferi* strain B31 locus tags (e.g. BB_0001) in the resulting GenBank file by local BLASTP analysis
589 of the *B. burgdorferi* 297 proteome against the proteome of *B. burgdorferi* B31 (Assembly ASM868v2).
590 The PGAP-annotated assembly of the complete *B. burgdorferi* 297 genome, including the here
591 assembled linear chromosome prior to flanking sequence removal, together with the BLAST-based ORF
592 annotation file, is provided in the **Supplemental materials**.

593

594 **Analysis of cells fractions by quantitative label free mass spectrometry.** 50 µg of each cell fraction
595 was precipitated by trichloroacetic acid (TCA)/acetone as described (62) for analysis by multidimensional
596 protein identification technology (MudPIT) mass spectrometry (63). Briefly, peptides eluted at every step
597 of a 10-step LC/MS process were searched against a *Borrelia burgdorferi* 297 protein sequence database
598 using the ProLuCID search engine. The result files from the ProLuCID search engine were processed
599 with DTASelect (v 1.9) to assemble peptide level information into protein level information. In-house
600 software, swallow and sandmartin (v 0.0.1), worked with DTASelect to select Peptide Spectrum Matches
601 such that the FDRs at the peptide and protein levels were less than 1%. Peptides and proteins detected
602 in the 12 samples were compared using CONTRAST. Proteins that were subsets of others were removed
603 using the parsimony option in DTASelect after merging all runs. Proteins that were identified by the same
604 set of peptides (including at least one peptide unique to such protein group to distinguish between
605 isoforms) were grouped together, and one accession number was arbitrarily considered as representative
606 of each protein group. In-house quantitative software, NSAF7 (v 0.0.1), was used to create a quantitative
607 Contrast Report on all detected peptides and non-redundant proteins identified across the different runs.
608 These data were analyzed in R with filtering for proteins detected in at least 2 of the 3 biological replicates
609 for each fraction. The standard error for fraction ratios was calculated with propagation of uncertainty. All
610 proteins with significant OMV and PC abundance changes identified by this analysis are listed in
611 Supplemental Tables S2 and S3, respectively.

612 **SDS-PAGE and immunoblotting for protein expression analysis.** *B. burgdorferi* cells were harvested
613 by centrifugation in a swinging bucket at 3,000 × *g* for 30 min at room temperature. Harvested cells were
614 washed twice with dPBS+Mg and resuspended in standard 1× SDS sample buffer (41). Whole-cell
615 lysates were resolved by 12% or 18% SDS-PAGE and visualized by Coomassie staining (Fisher;
616 BP3620-1). For immunoblotting, proteins were electrophoretically transferred overnight at 4°C to 0.1 μm
617 nitrocellulose blotting membrane (GE, 10600000) using a Bio-Rad Mini Trans-Blot apparatus at 30 V with
618 prechilled transfer buffer (25 mM Tris, 200 mM glycine, and 20% methanol). Membranes were blocked
619 for 30 min in TBST buffer (25 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.2) with 5% dry milk before
620 incubating on a rocker overnight at 4°C with either mouse anti-FLAG (1:5,000 dilution; Thermo Scientific,
621 MA191878), rat anti-BB0346-HIS (1:5,000 dilution), rat anti-FlaB (1:4,000 dilution; reference (64), mouse
622 anti-OspA (1:10,000 dilution; H5332; reference (65)), rat anti-OppAIV (1:5,000 dilution, a gift from M.
623 Caimano, University of Connecticut Health Center), mouse anti-P66 (1:500 dilution; H1337; reference
624 (66)), or mouse anti-Lp6.6 (1:10; reference (7)) primary antibodies. After three 10-minute washes with
625 TBST, the blots were incubated at room temperature on a rocker for 1 h with secondary anti-mouse IgG-
626 HRP (Sigma; A4416) or anti-rat IgG-HRP (Thermo Scientific; 31470) antibody. After three additional 10-
627 minute TBST washes, membranes were allowed to react with Super Signal West Femto (Thermo
628 Scientific; 34096) substrate per manufacturer instructions. Chemiluminescence was detected with
629 automatic exposure settings on an Amersham ImageQuant™ 800 (Cytiva).

630

631 **Accession codes.** *B. burgdorferi* LolA coordinates and structure factors have been deposited to the
632 Worldwide Protein Databank (wwPDB) with the accession codes 7TPM (PEG bound) and 8T5T (steric
633 acid bound). Assembled genome sequences for *B. burgdorferi* 297 are available in the GenBank
634 database under accession numbers CP152378 (chromosome) and CP152379 (cp26). Raw MudPIT label
635 free quantitative mass spectrometry data are available in the MassIVE database under accession number
636 MSV000095380.

637 **ACKNOWLEDGEMENTS**

638 We thank Jing Liu for the initial cloning of the *B. burgdorferi* *loIA* sequence, Hajime Tokuda for sharing
639 *E. coli* strains, and Jessica Kueker for the preliminary complementation experiments. Work at KUMC was
640 supported in part by NIH/NIAID Grants R21AI144624 and R21AI178835 and KU Endowment/Bryan
641 Lynch Family Foundation (to W.R.Z.). Work at UAMS was supported by NIH/NIAID grants R01AI087678
642 and R21AI119532 (to J.S.B.), the UAMS Center for Microbial Pathogenesis and Host Inflammatory
643 Responses (supported by NIH/NIGMS grant P20GM103625 to J.S.B.), and the UAMS IMSD program
644 (NIGMS R25GM083247 to D.E.G.). Use of the KU Protein Structure Laboratory was supported by
645 NIH/NIGMS grant P30 GM110761. This project has also been in part supported by Federal funds from
646 NIH/NIAID/DHHS Contract No. 75N93022C00036. Use of the IMCA-CAT beamline 17-ID at the
647 Advanced Photon Source was supported by the companies of the Industrial Macromolecular
648 Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute.
649 Use of the Advanced Photon Source was supported by the U.S. DOE, Office of Science, Office of Basic
650 Energy Sciences, under Contract No. DE-AC02-06CH11357. This research used resources the NYX
651 beamline 19-ID, supported by the New York Structural Biology Center, at the National Synchrotron Light
652 Source II, a U.S. DOE Office of Science User Facility operated for the DOE Office of Science by
653 Brookhaven National Laboratory under Contract No. DE-SC0012704. The NYX detector instrumentation
654 was supported by grant S10OD030394 through the Office of the Director of the NIH. S.K.S. and L.F. were
655 supported by the Stowers Institute.

656

657 REFERENCES

- 658 1. **Zückert WR.** 2019. Protein Secretion in Spirochetes. *Microbiol Spectr* **7**.
- 659 2. **Radolf JD, Caimano MJ, Stevenson B, Hu LT.** 2012. Of ticks, mice and men: understanding
660 the dual-host lifestyle of Lyme disease spirochaetes. *Nat Rev Microbiol* **10**:87-99.
- 661 3. **Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, Mead PS.** 2016.
662 Lyme borreliosis. *Nat Rev Dis Primers* **2**:16090.

- 663 4. **He H, Pramanik AS, Swanson SK, Johnson DK, Florens L, Zückert WR.** 2023. A *Borrelia*
664 burgdorferi LptD homolog is required for flipping of surface lipoproteins through the spirochetal
665 outer membrane. *Mol Microbiol* **119**:752-767.
- 666 5. **Dowdell AS, Murphy MD, Azodi C, Swanson SK, Florens L, Chen S, Zückert WR.** 2017.
667 Comprehensive Spatial Analysis of the *Borrelia burgdorferi* Lipoproteome Reveals a
668 Compartmentalization Bias toward the Bacterial Surface. *J Bacteriol* **199**.
- 669 6. **Katona LI, Beck G, Habicht GS.** 1992. Purification and immunological characterization of a
670 major low-molecular-weight lipoprotein from *Borrelia burgdorferi*. *Infect Immun* **60**:4995-5003.
- 671 7. **Lahdenne P, Porcella SF, Hagman KE, Akins DR, Popova TG, Cox DL, Katona LI, Radolf**
672 **JD, Norgard MV.** 1997. Molecular characterization of a 6.6-kilodalton *Borrelia burgdorferi* outer
673 membrane-associated lipoprotein (lp6.6) which appears to be downregulated during mammalian
674 infection. *Infect Immun* **65**:412-421.
- 675 8. **Promnares K, Kumar M, Shroder DY, Zhang X, Anderson JF, Pal U.** 2009. *Borrelia*
676 burgdorferi small lipoprotein Lp6.6 is a member of multiple protein complexes in the outer
677 membrane and facilitates pathogen transmission from ticks to mice. *Mol Microbiol* **74**:112-125.
- 678 9. **Hart T, Yang X, Pal U, Lin YP.** 2018. Identification of Lyme borreliae proteins promoting
679 vertebrate host blood-specific spirochete survival in *Ixodes scapularis* nymphs using artificial
680 feeding chambers. *Ticks Tick Borne Dis* **9**:1057-1063.
- 681 10. **Stewart PE, Hoff J, Fischer E, Krum JG, Rosa PA.** 2004. Genome-wide transposon
682 mutagenesis of *Borrelia burgdorferi* for identification of phenotypic mutants. *Appl Environ*
683 *Microbiol* **70**:5973-5979.
- 684 11. **Kariu T, Yang X, Marks CB, Zhang X, Pal U.** 2013. Proteolysis of BB0323 results in two
685 polypeptides that impact physiologic and infectious phenotypes in *Borrelia burgdorferi*. *Mol*
686 *Microbiol* **88**:510-522.
- 687 12. **Zhang X, Yang X, Kumar M, Pal U.** 2009. BB0323 function is essential for *Borrelia burgdorferi*
688 virulence and persistence through tick-rodent transmission cycle. *J Infect Dis* **200**:1318-1330.

- 689 13. **Lenhart TR, Kenedy MR, Yang X, Pal U, Akins DR.** 2012. BB0324 and BB0028 are
690 constituents of the *Borrelia burgdorferi* beta-barrel assembly machine (BAM) complex. *BMC*
691 *Microbiol* **12**:60.
- 692 14. **Zückert WR.** 2014. Secretion of bacterial lipoproteins: through the cytoplasmic membrane, the
693 periplasm and beyond. *Biochim Biophys Acta* **1843**:1509-1516.
- 694 15. **Narita SI, Tokuda H.** 2017. Bacterial lipoproteins; biogenesis, sorting and quality control.
695 *Biochim Biophys Acta Mol Cell Biol Lipids* **1862**:1414-1423.
- 696 16. **Miyamoto S, Tokuda H.** 2007. Diverse effects of phospholipids on lipoprotein sorting and ATP
697 hydrolysis by the ABC transporter LolCDE complex. *Biochim Biophys Acta* **1768**:1848-1854.
- 698 17. **Wang XG, Scagliotti JP, Hu LT.** 2004. Phospholipid synthesis in *Borrelia burgdorferi*: BB0249
699 and BB0721 encode functional phosphatidylcholine synthase and
700 phosphatidylglycerolphosphate synthase proteins. *Microbiology (Reading)* **150**:391-397.
- 701 18. **Schulze RJ, Zückert WR.** 2006. *Borrelia burgdorferi* lipoproteins are secreted to the outer
702 surface by default. *Mol Microbiol* **59**:1473-1484.
- 703 19. **Kumru OS, Schulze RJ, Rodnin MV, Ladokhin AS, Zückert WR.** 2011. Surface localization
704 determinants of *Borrelia* OspC/Vsp family lipoproteins. *J Bacteriol* **193**:2814-2825.
- 705 20. **Hayashi Y, Tsurumizu R, Tsukahara J, Takeda K, Narita SI, Mori M, Miki K, Tokuda H.**
706 2014. Roles of the protruding loop of factor B essential for the localization of lipoproteins (LolB)
707 in the anchoring of bacterial triacylated proteins to the outer membrane. *J Biol Chem*
708 **289**:10530-10539.
- 709 21. **Teufel F, Almagro Armenteros JJ, Johansen AR, Gislason MH, Pihl SI, Tsirigos KD,**
710 **Winther O, Brunak S, von Heijne G, Nielsen H.** 2022. SignalP 6.0 predicts all five types of
711 signal peptides using protein language models. *Nat Biotechnol* **40**:1023-1025.
- 712 22. **Tajima T, Yokota N, Matsuyama S, Tokuda H.** 1998. Genetic analyses of the in vivo function
713 of LolA, a periplasmic chaperone involved in the outer membrane localization of *Escherichia coli*
714 lipoproteins. *FEBS Lett* **439**:51-54.

- 715 23. **Smith HC, May KL, Grabowicz M.** 2023. Teasing apart the evolution of lipoprotein trafficking in
716 gram-negative bacteria reveals a bifunctional LolA. *Proc Natl Acad Sci U S A*
717 **120**:e2218473120.
- 718 24. **Yakushi T, Tajima T, Matsuyama S, Tokuda H.** 1997. Lethality of the covalent linkage
719 between mislocalized major outer membrane lipoprotein and the peptidoglycan of *Escherichia*
720 *coli*. *J Bacteriol* **179**:2857-2862.
- 721 25. **Krissinel E, Henrick K.** 2007. Inference of macromolecular assemblies from crystalline state. *J*
722 *Mol Biol* **372**:774-797.
- 723 26. **Krissinel E, Henrick K.** 2004. Secondary-structure matching (SSM), a new tool for fast protein
724 structure alignment in three dimensions. *Acta Crystallographica Section D* **60**:2256-2268.
- 725 27. **Oguchi Y, Takeda K, Watanabe S, Yokota N, Miki K, Tokuda H.** 2008. Opening and closing
726 of the hydrophobic cavity of LolA coupled to lipoprotein binding and release. *J Biol Chem*
727 **283**:25414-25420.
- 728 28. **Kaplan E, Greene NP, Jepson AE, Koronakis V.** 2022. Structural basis of lipoprotein
729 recognition by the bacterial Lol trafficking chaperone LolA. *Proc Natl Acad Sci U S A*
730 **119**:e2208662119.
- 731 29. **Bunikis J, Barbour AG.** 1999. Access of antibody or trypsin to an integral outer membrane
732 protein (P66) of *Borrelia burgdorferi* is hindered by Osp lipoproteins. *Infect Immun* **67**:2874-
733 2883.
- 734 30. **Skare JT, Shang ES, Foley DM, Blanco DR, Champion CI, Mirzabekov T, Sokolov Y,**
735 **Kagan BL, Miller JN, Lovett MA.** 1995. Virulent strain associated outer membrane proteins of
736 *Borrelia burgdorferi*. *J Clin Invest* **96**:2380-2392.
- 737 31. **Tsukahara J, Mukaiyama K, Okuda S, Narita S, Tokuda H.** 2009. Dissection of LolB function-
738 -lipoprotein binding, membrane targeting and incorporation of lipoproteins into lipid bilayers.
739 *FEBS J* **276**:4496-4504.

- 740 32. **Malinverni JC, Silhavy TJ.** 2009. An ABC transport system that maintains lipid asymmetry in
741 the gram-negative outer membrane. *Proc Natl Acad Sci U S A* **106**:8009-8014.
- 742 33. **Low WY, Chng SS.** 2021. Current mechanistic understanding of intermembrane lipid trafficking
743 important for maintenance of bacterial outer membrane lipid asymmetry. *Curr Opin Chem Biol*
744 **65**:163-171.
- 745 34. **Blevins JS, Revel AT, Smith AH, Bachlani GN, Norgard MV.** 2007. Adaptation of a
746 Luciferase Gene Reporter and lac Expression System to *Borrelia burgdorferi*. *Applied and*
747 *Environmental Microbiology* **73**:1501–1513.
- 748 35. **Guzman LM, Belin D, Carson MJ, Beckwith J.** 1995. Tight regulation, modulation, and high-
749 level expression by vectors containing the arabinose PBAD promoter. *J Bacteriol* **177**:4121-
750 4130.
- 751 36. **Olins PO, Rangwala SH.** 1989. A novel sequence element derived from bacteriophage T7
752 mRNA acts as an enhancer of translation of the lacZ gene in *Escherichia coli*. *J Biol Chem*
753 **264**:16973-16976.
- 754 37. **Samuels DS.** 1995. Electrotransformation of the Spirochete *Borrelia burgdorferi*, p 253–260. *In*
755 *Nickoloff JA (ed), Electroporation Protocols for Microorganisms*, vol 47. Humana Press, New
756 Jersey.
- 757 38. **Yang XF, Pal U, Alani SM, Fikrig E, Norgard MV.** 2004. Essential Role for OspA/B in the Life
758 Cycle of the Lyme Disease Spirochete. *Journal of Experimental Medicine* **199**:641–648.
- 759 39. **Blevins JS, Hagman KE, Norgard MV.** 2008. Assessment of decorin-binding protein A to the
760 infectivity of *Borrelia burgdorferi* in the murine models of needle and tick infection. *BMC*
761 *Microbiol* **8**:82.
- 762 40. **Revel AT, Blevins JS, Almazan C, Neil L, Kocan KM, de la Fuente J, Hagman KE, Norgard**
763 **MV.** 2005. bptA (bbe16) is essential for the persistence of the Lyme disease spirochete, *Borrelia*
764 *burgdorferi*, in its natural tick vector. *Proc Natl Acad Sci U S A* **102**:6972-6977.


- 765 41. **J S.** 2001. Molecular cloning: a laboratory manual, 3 ed. Cold Spring Harbor Laboratory Press,
766 Cold Spring Harbor, NY.
- 767 42. **de Leeuw BH, Maraha B, Hollemans L, Sprong H, Brandenburg AH, Westenend PJ,**
768 **Kusters JG.** 2014. Evaluation of *Borrelia* real time PCR DNA targeting *OspA*, *FlaB* and *5S-23S*
769 IGS and *Borrelia* 16S rRNA RT-qPCR. *J Microbiol Methods* **107**:41-46.
- 770 43. **Pereira JH, McAndrew RP, Tomaleri GP, Adams PD.** 2017. Berkeley Screen: a set of 96
771 solutions for general macromolecular crystallization. *J Appl Crystallogr* **50**:1352-1358.
- 772 44. **Kabsch W.** 1988. Automatic indexing of rotation diffraction patterns. *Journal of Applied*
773 *Crystallography* **21**:67-72.
- 774 45. **Kabsch W.** 2010. Xds. *Acta Crystallogr D Biol Crystallogr* **66**:125-132.
- 775 46. **Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, Bricogne**
776 **G.** 2011. Data processing and analysis with the autoPROC toolbox. *Acta Crystallogr D Biol*
777 *Crystallogr* **67**:293-302.
- 778 47. **Evans PR.** 2011. An introduction to data reduction: space-group determination, scaling and
779 intensity statistics. *Acta Crystallogr D Biol Crystallogr* **67**:282-292.
- 780 48. **Skubak P, Pannu NS.** 2013. Automatic protein structure solution from weak X-ray data. *Nat*
781 *Commun* **4**:2777.
- 782 49. **Sheldrick GM.** 2010. Experimental phasing with SHELXC/D/E: combining chain tracing with
783 density modification. *Acta Crystallogr D Biol Crystallogr* **66**:479-485.
- 784 50. **Murshudov GN, Vagin AA, Dodson EJ.** 1997. Refinement of macromolecular structures by
785 the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr* **53**:240-255.
- 786 51. **Abrahams JP, Leslie AGW.** 1996. Methods used in the structure determination of bovine
787 mitochondrial F1 ATPase. *Acta Crystallographica Section D* **52**:30-42.
- 788 52. **Zhang KYJ, Cowtan K, Main P.** 1997. [4] Combining constraints for electron-density
789 modification, p 53-64, *Methods in Enzymology*, vol 277. Academic Press.

- 790 53. **Cowtan K.** 2006. The Buccaneer software for automated model building. 1. Tracing protein
791 chains. *Acta Crystallogr D Biol Crystallogr* **62**:1002-1011.
- 792 54. **Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM,**
793 **Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton**
794 **EA, Powell HR, Read RJ, Vagin A, Wilson KS.** 2011. Overview of the CCP4 suite and current
795 developments. *Acta Crystallogr D Biol Crystallogr* **67**:235-242.
- 796 55. **McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ.** 2007.
797 *Phaser* crystallographic software. *J Appl Cryst* **40**:658-674.
- 798 56. **Emsley P, Lohkamp B, Scott WG, Cowtan K.** 2010. Features and development of Coot. *Acta*
799 *Crystallogr D Biol Crystallogr* **66**:486-501.
- 800 57. **Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW,**
801 **Richardson JS, Richardson DC.** 2010. MolProbity: all-atom structure validation for
802 macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* **66**:12-21.
- 803 58. **Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P, Murshudov GN,**
804 **Cohen S, Perrakis A, Noble M.** 2004. Developments in the CCP4 molecular-graphics project.
805 *Acta Crystallogr D Biol Crystallogr* **60**:2288-2294.
- 806 59. **Wick RR, Judd LM, Holt KE.** 2023. Assembling the perfect bacterial genome using Oxford
807 Nanopore and Illumina sequencing. *PLoS Comput Biol* **19**:e1010905.
- 808 60. **Schutzer SE, Fraser-Liggett CM, Casjens SR, Qiu WG, Dunn JJ, Mongodin EF, Luft BJ.**
809 2011. Whole-genome sequences of thirteen isolates of *Borrelia burgdorferi*. *J Bacteriol*
810 **193**:1018-1020.
- 811 61. **Barbour AG, Garon CF.** 1987. Linear plasmids of the bacterium *Borrelia burgdorferi* have
812 covalently closed ends. *Science* **237**:409-411.
- 813 62. **Link AJ, LaBaer J.** 2011. Trichloroacetic acid (TCA) precipitation of proteins. *Cold Spring Harb*
814 *Protoc* **2011**:993-994.

- 815 63. **Washburn MP, Wolters D, Yates JR, 3rd.** 2001. Large-scale analysis of the yeast proteome by
816 multidimensional protein identification technology. *Nat Biotechnol* **19**:242-247.
- 817 64. **Caimano MJ, Eggers CH, Gonzalez CA, Radolf JD.** 2005. Alternate Sigma Factor RpoS Is
818 Required for the In Vivo-Specific Repression of *Borrelia burgdorferi* Plasmid lp54-Borne ospA
819 and lp6.6 Genes. *Journal of Bacteriology* **187**:7845–7852.
- 820 65. **Barbour AG, Tessier SL, Todd WJ.** 1983. Lyme disease spirochetes and ixodid tick
821 spirochetes share a common surface antigenic determinant defined by a monoclonal antibody.
822 *Infect Immun* **41**:795-804.
- 823 66. **Bunikis J, Luke CJ, Bunikiene E, Bergström S, Barbour AG.** 1998. A surface-exposed
824 region of a novel outer membrane protein (P66) of *Borrelia* spp. is variable in size and
825 sequence. *J Bacteriol* **180**:1618-1623.
- 826
- 827

828 **FIGURES**

829 **Figure 1**



830

831 **Fig. 1. Complementation assay showing incompatibility of LolA_{Bb} with the *E. coli* Lol pathway. (A)**

832 Comparison of LolA secretory signal I peptides (SSI) in *B. burgdorferi* (Bb) and *E. coli* (Ec). The three

833 regions of SSI peptides, including a positively charged N terminus (N), hydrophobic α-helix (H), and

834 flexible C region (C), are denoted before the predicted signal peptidase I processing site (*). (B)

835 Processing of heterologous LolA SSIs in *E. coli* and *B. burgdorferi*. C-terminally FLAG-tagged mature

836 LolA_{Bb} (mLolA_{Bb}-FLAG) fused to either *E. coli* or *B. burgdorferi* SSIs were overexpressed from P_{lac}

837 promoters in *E. coli* or *B. burgdorferi*, and whole cell lysates were analyzed by immunoblotting with anti-

838 FLAG antibody. Note that the SSI_{Bb}-mLolA_{Bb}-FLAG fusion corresponds to a C-terminally FLAG-tagged

839 w.t. LolA_{Bb} protein, marking the size of the properly processed LolA_{Bb}. (C) Serial dilution spot plating of


840 *E. coli* strain TT011 (P_{lac}-*lolA*_{Ec}; (22)) harboring pBAD33 plasmid derivatives expressing various LolA

841 constructs from the P_{ara} promoter on LB agar containing 0.2% arabinose (Ara) with (+) or without (-) 1mM

842 IPTG. SSI_{Ec}-mLolA_{Bb}CO includes mLolA_{Bb} that is codon-optimized for *E. coli*. SSI_{Ec}-mLolA_{Bb}COChim is the C-

843 terminal chimera based on the *C. vibrioides*/*E. coli* LolA chimera described by Smith and colleagues (23);
844 see also **Supplemental Data**). Strains containing empty pBAD33 vector and recombinant *E. coli* LolA
845 (LolA_{Ec})-expressing plasmids were included as negative and positive controls. Expression of the non-
846 complementing LolA proteins was ascertained by Western immunoblotting (**Supplemental Data Fig.**
847 **S1A**)
848


849 **Figure 2**



850

851 **Fig. 2. X-ray crystal structure of LolA_{Bb}-PEG.** (A) Ribbons rendering colored by secondary structure
852 with α-helices (cyan) and β-sheets (magenta) indicated. N, N terminus; C, C terminus. An asterisk (*)
853 indicates the location of a unique protruding loop between β7 and β8. (B) View of LolA_{Bb}-PEG along and
854 perpendicular to the β-barrel axis. (C) Secondary structure elements are annotated relative to the
855 mLolA_{Bb}-his sequence excluding C-terminal purification tag residues (see **Supplemental Data Fig. S3A**).
856 (D) Fo-Fc omit electron density map (green mesh) contoured at 3σ showing the PEG molecule bound to
857 LolA_{Bb}. © Interaction of PEG with LolA_{Bb}-PEG. In the left panel, the PEG molecule (gray/red cylinders) is
858 shown to be surrounded mainly by hydrophobic residues (cyan). The direct hydrogen bond to Y41 and
859 water mediated contact with S60 is indicated by the dashed lines. The right panel shows an electrostatic
860 surface representation of the LolA_{Bb}-PEG residues surrounding the PEG molecule (green).

861 **Figure 3**




862

863 **Fig. 3. Structural differences between the hydrophobic pockets of LolA homologs.** LolA_{Bb}-PEG
864 was superimposed with the LolA structures of **(A)** *P. aeruginosa* (2W7Q, gold), **(B)** *E. coli* (1IWL, coral),
865 **(C)** *N. europaea* (3BUU, green) and **(D)** *Y. pestis* (4KI3, cyan) onto LolA_{Bb} (magenta). The PEG molecule
866 from LolA_{Bb} is rendered as gray/red spheres. The additional α -helix present in the other LolA structures
867 is indicated by asterisks.

868

869 **Figure 4**




870

871 **Fig. 4. Structural comparison of LolA_{Bb} and *E. coli* LolB.** (A) The structure of *E. coli* LolA (1IWN, blue)
872 was superposed onto LolA_{Bb}-PEG (magenta). The PEG molecule is rendered in gray/red spheres for
873 LolA_{Bb}-PEG and in green/red spheres for LolB. Localization of the two protruding loops in LolA_{Bb} and *E.*
874 *coli* LolB are indicated with colored asterisks. (B) Binding modes for the PEG molecules bound to LolB
875 (green/red) and LolA_{Bb} (gray/red). (C) Rotation of superimposed structures shown in panel A to better
876 illustrate the localization of the two loops, marked with colored asterisks as in panel A. The functionally
877 relevant *E. coli* LolB L68 residue and a similarly prominent LolA_{Bb} L110 residue of are shown as sticks.

878

879 **Figure 5**




880

881 **Fig. 5. Structural differences between LolA homologs in the $\beta 7$ - $\beta 8$ connecting loop.** LolA_{Bb}-PEG
882 was superimposed with the LolA structures of (A) *P. aeruginosa* (2W7Q, gold), (B) *E. coli* (1IWL, coral),
883 (C) *N. europaea* (3BUU, green) and (D) *Y. pestis* (4KI3, cyan) onto LolA_{Bb} (magenta). The turn between
884 antiparallel $\beta 7$ and $\beta 8$ sheets present in the other LolA structures is indicated by asterisks.

885

886

Figure 6




887

888 **Fig. 6. Phenotypic analysis of LoIA_{Bb} depletion in *B. burgdorferi*.** (A) Liquid culture growth curves.
 889 Spirochetes were inoculated at 1×10^5 cells/mL and grown with or without IPTG to control expression of
 890 LoIA_{Bb} in a recombinant *B. burgdorferi* strain carrying its sole plasmid-encoded *loIA_{Bb}* allele under *lac*
 891 promoter control (see Materials & Methods). Growth curves are from 3 biological replicates. Error bars
 892 indicate mean \pm 95% confidence interval. Significance was calculated by 2-way ANOVA; *** $P \leq 0.001$;
 893 **** $P \leq 0.0001$; NS, $P > 0.05$. (B) Phase contrast micrographs depicting the effects of LoIA_{Bb} depletion (-
 894 IPTG) on cell morphology in comparison to control cells (+ IPTG) on day 2. (C) Expression levels of
 895 LoIA_{Bb} in w.t. and recombinant conditional knockdown strains. Periplasmic flagellar protein FlaB served
 896 as a loading control. Expression levels relative to w.t. cells were determined by densitometry
 897 measurements of Western immunoblot bands from 3 biological replicates. (D) Schematic depiction of
 898 modified surface protein accessibility assay (see text). (E) Surface accessibility of lipoproteins using a
 899 modified PK shaving/reshaving assay (see panel D), as analyzed by Commais-stained SDS-PAGE,

900 Coomassie staining and Western immunoblotting. Highly abundant OspA served as the model surface
901 lipoprotein. OM porin P66 served as a non-lipoprotein OM control; note that after PK cleavage of a
902 surface-accessible loop, a P66 fragment band (P66*) appears. Periplasmic flagellar protein FlaB was
903 used as an OM integrity and constitutively expressed loading control. OppAIV and Lp6.6 served as
904 sentinel inner membrane and subsurface lipoprotein controls, respectively. **(F)** Fractionated protoplasmic
905 cylinder (PC) and outer membrane vesicle (OMV) fractions were assessed as in **panel E**. Note that the
906 PC fraction also contains intact cells.
907


908 **Figure 7**



909

910 **Fig. 7. MudPIT analysis of *B. burgdorferi* conditional knockout strain cell fractions.** dNSAF values
911 indicating abundance of selected inner membrane (IM), outer membrane (OM) and periplasmic (P)
912 proteins in the protoplasmic cylinder (PC) and outer membrane vesicle (OMV) fractions are plotted. +
913 IPTG, LoIA replete control conditions; - IPTG, LoIA depleting conditions. Samples were taken at day 1
914 (24 hours depletion). Note that the PC fraction also contains remaining intact cells. Data are from 3
915 parallel biological replicates. Error bars indicate mean \pm SEM.

916 **Figure 8**



917

918 **Fig. 8. MudPIT analysis of *B. burgdorferi* conditional knockout strain cell fractions.** dNSAF values

919 indicating abundance of periplasmic inner membrane (P-IM), periplasmic outer membrane (P-OM) and

920 surface lipoproteins consistently detected in the outer membrane vesicle (OMV) fraction were used to
921 determine dNSAF ratios indicating a change in abundance. dNSAF ratios of LoIA depleted (- IPTG)
922 dNSAF value/LoIA replete (+IPTG) are plotted. Samples were taken at day 1 (24 hours depletion). Data
923 are from 3 parallel biological replicates. Error bars indicate mean \pm SEM, with propagation of uncertainty
924 for ratio values. Column shading indicates the dNSAF-derived abundance of proteins under LoIA replete
925 control conditions; e.g., OspA (yellow) is much more abundant in the sample than BBA14 (purple).